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Available online 5 November 2013Abstract Vascular smooth muscle cells represent a major component of the cardiovascular system. In vitro studies have
shown that FLK1+ cells derived from embryonic stem (ES) cells can differentiate into both endothelial and smooth muscle cells.
These FLK1+ cells also contain a mesodermal precursor, the hemangioblast, able to produce endothelial, blood and smooth
muscle cells. The generation of blood precursors from the hemangioblast was recently shown to occur through a transient cell
population of specialised endothelium, a hemogenic endothelium. To date, the lineage relationship between this cell
population and smooth muscle cell progenitors has not been investigated. In this study, we generated a reporter ES cell line in
which expression of the fluorescent protein H2B-VENUS is driven by the α-smooth muscle actin (α-SMA) regulatory sequences.
We demonstrated that this reporter cell line efficiently trace smooth muscle development during ES cell differentiation.
Although some smooth muscle cells are associated with broad endothelial development, we established that smooth muscle
cells are mostly generated independently from a specialised functional hemogenic endothelium. This study provides new and
important insights into hematopoietic and vascular development, which may help in driving further progress towards the
development of bioengineered vascular grafts for regenerative medicine.
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Open access unIntroduction
The blood vessel and hematopoietic systems are the first
functional organs formed in the developing embryo. Endothe-
lial cells are initially generated through vasculogenesis to
produce a primitive vascular plexus. Subsequent angiogenesis
lead to the expansion and remodelling of this initial endothelial
network (Patan, 2004). The newly formed endothelial vessels
become rapidly associated with mural cells of the smooth
muscle cell lineage. These cells are either referred to asder the CC BY-NC-ND license.
223Smooth muscle cells largely develop independently of functional hemogenic endotheliumvascular smoothmuscle cells if they encircle larger vessels or as
pericytes if they reside within the wall of small vessels such as
capillaries and post-capillary venules. These cells regulate
blood flow through contraction and have also been proposed to
control endothelial cell proliferation and differentiation by
direct signalling and deposition of extracellular matrix
(Betsholtz et al., 2005). Hampered smooth muscle cell
differentiation or function results in severe vascular defects
such as abnormal vessel morphology and increased permeabil-
ity leading to a number of cardiovascular disorders including
congenital heart diseases, aortic aneurysm, atherosclerosis,
hypertension, and restenosis (Carvalho et al., 2004; Guo et
al., 2007; Hellstrom et al., 2001, 1999; Lindahl et al., 1997;
Milewicz et al., 2008; Zhu et al., 2006). In Hutchinson–Gilford
progeria syndrome, loss of smooth muscle cells has been
suggested to lead to progressive arterial occlusion that causes
death frommyocardial infarction or from stroke at an average
age of thirteen years (Varga et al., 2006).
Smooth muscle cells are characterised by the specific
expression of several proteins such as α-smooth muscle actin
(α-SMA), transgelin (SM22α), calponin and smooth muscle
myosin heavy chain (MYH11) (Owens, 1995). α-SMA, encoded
by the Acta2 gene, is one of the six actin genes expressed in
mammalian cells and is the first knownmarker of differentiated
smooth muscle cells during vasculogenesis (Owens, 1995).
During murine embryogenesis, vascular smooth muscle cells
express high levels of α-SMA, (Mack and Owens, 1999; McHugh,
1995), initially within the embryonic heart rudiment around
E8.5, then in the yolk sac and the aorta vasculature by E9.5–
10.5 (Armstrong et al., 2010). The embryonic origin of smooth
muscle remains poorly characterised and lineage-tracing
studies suggest that, in distinct vessels, vascular smooth
muscles or pericytes have different embryonic origins (Cheung
et al., 2012; Majesky, 2007). The hemangioblast, or its in vitro
equivalent — the blast colony forming cell (BL-CFC), is defined
as a mesodermal progenitor cell with endothelial and hemato-
poietic potentials (Choi et al., 1998). A vascular smooth muscle
cell developmental potential was also attributed to the
hemangioblast, as both embryo-derived hemangioblast (Huber
et al., 2004) and embryonic stem (ES) cell-derived BL-CFCs
(Ema et al., 2003; Lu et al., 2009) were demonstrated to
contain vascular smooth muscle potential. The generation of
blood precursors from the hemangioblast was recently shown
to occur through a transient cell population of specialised
endothelium, a hemogenic endothelium (Lancrin et al., 2009).
To date, the lineage relationship between this specific
endothelial cell population and smooth muscle cell progeni-
tors has not been investigated. Several previous studies
suggest a close developmental relationship between endothe-
lial and smooth muscle progenitors. For instance, mesodermal
FLK1+ cells generated from differentiated ES cells were shown
to produce both smooth muscle and endothelial cells that
organise into vessel-like structures (Yamashita et al., 2000).
Furthermore, smoothmuscle actin expression has been detected
in CD34+ cord blood endothelium and in endothelial cells at the
luminal surface of adult aorta (Azuma et al., 2009; Lu et al.,
2004). The generation of cardiomyocytes was also shown to be
associated with common endothelial and smooth muscle
development. In headfold stage murine embryos, or in differen-
tiated ES cells, Kattman et al. identified a progenitor for
cardiomyocytes with additional endothelial and vascular smooth
muscle potential (Kattman et al., 2006; Yang et al., 2008).In this study, we generated a mouse reporter ES cell line in
which the expression of the fluorescent protein, H2B-VENUS,
is driven from α-SMA regulatory sequences. We demonstrated
that this reporter cell line allows to efficiently track smooth
muscle development during murine ES cell differentiation.
Although we observed the presence of rare H2B-VENUS+ cells
in enriched hemogenic endothelial cell populations, our
findings established that smooth muscle cells were mostly
generated independently from the specialised functional
hemogenic endothelium.
Materials and methods
BAC recombineering
The bMQ116k23 BAC was purchased from the Sanger Institute.
BAC carrying bacteria were transformed with pSC101-
BAD-gbaA plasmid containing recombination proteins: exo,
bet and gam under the control of arabinose-inducible
promoter (gift from Francis Stewart laboratory, Dresden).
The homology arms were cloned into a vector containing:
H2B-Venus reporter gene, a floxed cassette PGK/EM7-TK-Neo
and an ampicillin resistance gene. Recombineering was
performed according to the method developed by Francis
Stewart laboratory (Dresden, Germany). Details of oligonu-
cleotides sequences used for various steps and screening of ES
cells are available on request.
Gene expression analysis
Total RNA was extracted using RNeasy Plus Mini Kit (Qiagen).
cDNA was generated using Omniscript RT Kit (Qiagen).
Quantitative PCR was performed on ABI7900 (Applied
Biosystems) using universal probe library (Roche), TaqMan
Universal PCR Master Mix (Applied Biosystems) and gene
specific primers (Supplemental Table 1). Gene expression
was normalised to a reference gene (β-Actin) and represent-
ed as 2^-ΔCt.
ES cell culture
Murine ES cells were maintained and differentiated as
described (Sroczynska et al., 2009b). Smooth muscle cells
were grown in medium containing IMDM supplemented with
10% FCS, 2 mM L-glutamine, 180 μg/ml transferrin, 25 μg/ml
ascorbic acid, 4.6 × 10−4 M MTG, 15% D4T conditioned
medium (Choi et al., 1998), 10 ng/ml IL-6 (Peprotech) and
5 ng/ml VEGF (Peprotech). For contraction assays, cells
were treated with carbachol (100 μM, Sigma) where indi-
cated. Hemogenic endothelial cultures were performed as
previously described (Lancrin et al., 2009). Single blast
colonies were expanded in the medium previously described
on a Ibidi μ-slide with Matrigel (Huber et al., 2004).
Fluorescence-activated cell sorting (FACS)
Flk1-bio, TIE2-bio, CD31-bio, c-KIT-APC, VE-CADHERIN-APC,
CD41-PE and Streptavidin-PECy7 antibodies were purchased
from eBioscience. α-SMA-Cy3 antibody was purchased from
Sigma. All antibodies used in this study have been previously
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225Smooth muscle cells largely develop independently of functional hemogenic endotheliumused and specifically label the correct cell populations when
compared to isotype controls (Lancrin et al., 2012; Gandillet
et al., 2009; Supplemental Fig. 1). The stained cells were
sorted on ARIA or Influx flow cytometers or analysed on a
FACS LSRII (Becton Dickinson). The staining data were
analysed using the FlowJo software (TreeStar). Non-viable
cells were excluded by gating forward scatter versus side
scatter first.
Immunofluorescence
Cells grown on 6 channel μ-slides (Ibidi) were fixed and
stained with the following primary antibodies, α-SMA-FITC,
clone 1A4 or α-SMA-Cy3, Clone 1A4 (Sigma). Slides were
mounted with ProLong Gold antifade reagent with DAPI
(Invitrogen). Images were acquired using an Axiovert 200 M
(Carl Zeiss, Germany) fluorescence microscope and data
were analysed using Metamorph software (Molecular
Devices).
Statistical analysis
Statistical analysis was performed using Student's t test.
Significant differences are indicated with *** if p b0.001.
Results
Generation and validation of a reporter α-Sma::
H2B-Venus ES cell line for smooth muscle cell
lineage
To be able to follow the development of smooth muscle
cells, we generated an α-Sma transgenic reporter ES cell
line. A BAC (bMQ116k23) containing the full α-Sma locus was
first modified by recombineering to encode for the expres-
sion of the nuclear fluorescent H2B-VENUS protein driven by
regulatory sequences of α-Sma (Fig. 1A). The modified BAC
was then electroporated in ES cells and several clones were
selected with geneticin (G418). These ES clones were next
differentiated as embryoid bodies (EBs) during one week and
each day the expression of the transgenic H2B-Venus was
compared to the expression of endogenous α-Sma. As shown
in Fig. 1B for one representative ES clone, the detection of
transcripts coding for the reporter H2B-Venus was tempo-
rally correlated with the presence of transcripts for the
endogenous α-Sma gene. For both genes, the transcripts
were clearly detected from day 5 of differentiation and their
levels increased dramatically over the next few days. The
presence of the H2B-VENUS fluorescent protein was also
evaluated by flow cytometry during this time course of ESFigure 1 Generation and validation of the transgenic α-Sma::H2B-
to create α-Sma::H2B-Venus BAC. HA1 and HA2 — homology arms 1 a
Neo — neomycin, E — exon. B) Quantitative PCR analysis of expressio
differentiation. Data are mean ± s.e.m. (n = 3). C) Representative F
D) FACS histograms show the percentage of α-SMA+ within H2B-VENUS
unstained control cells). Bars indicate mean ± s.e.m. (n = 3).cell differentiation (Fig. 1C). At day 5 of EB differentiation,
around 3% of cells expressed H2B-VENUS and the percentage
of positive cells reached 19% by day 7 (Fig. 1C). In addition,
flow cytometry analysis of intracellular staining for α-SMA
indicated that cells expressing α-Sma were highly enriched
in H2B-VENUS+ population (Fig. 1D).
To further confirm that H2B-VENUS+ population is
enriched in cells corresponding to the smooth muscle
lineage, positive and negative H2B-VENUS cells were isolated
at day 6 of EB differentiation and analysed by quantitative
PCR. The smooth muscle markers α-Sma, Sm22, Calponin 1
andMyh11 were detected at much higher levels in the sorted
H2B-VENUS+ population fraction than in the negative fraction
(Fig. 2A). We also analysed the expression of the cardiac
muscle markers Nkx2.5 and Tbx20 and detected low levels of
enrichment in H2B-VENUS+ cells (Fig. 2B). This finding is
consistent with a previous report of a bipotent myocardial
and smooth muscle progenitor (Wu et al., 2006). In contrast,
none of the ES-derived populations contained detectable
levels of the skeletal muscle-related transcript Myf5 or
Myogenin (Fig. 2C). Together, these results suggest that the
H2B-VENUS+ cell population is devoid of skeletal muscle cells
but we cannot exclude the existence of cardiac progenitors.
Upon replating, H2B-VENUS+ cells demonstrated typical
smooth muscle cell morphology as large, flat, adherent cells
with nuclei positive for H2B-VENUS fluorescence and
stained uniformly positive with an antibody against α-SMA
(Fig. 2D). Finally, when treated with carbachol, that
promotes intracellular calcium influx and induces contrac-
tion, H2B-VENUS+ showed a change in morphology, indicat-
ing that these cells possess the ability to contract
(Supplemental Fig. 2). Altogether these results demon-
strate that the expression of H2B-Venus from the transgenic
BAC reflects the endogenous expression of α-Sma in this
newly generated reporter α-Sma::H2B-Venus ES cell line. In
addition, our data strongly suggest that H2B-VENUS+ cells
correspond to smooth muscle cells, potentially restricted to
the vascular compartment.Tracking the emergence of smooth muscle cells
during blast colony differentiation
It has been previously reported that FLK1+ mesodermal cells
can differentiate towards endothelial and vascular smooth
muscle cells both in vitro and in vivo (Yamashita et al.,
2000). Other studies have also indicated that clonal
BL-CFCs, that are present within the earliest FLK1+ cell
population, possess in addition to endothelial and hemato-
poietic potential, a vascular smooth muscle potential (Ema
et al., 2003; Huber et al., 2004). To confirm these later
findings with the α-Sma::H2B-Venus reporter ES cell line,Venus ES cell line. A) Scheme of the recombination strategy used
nd 2, P α-Sma — promoter of α-Sma, EM7 — bacterial promoter,
n of endogenous α-Sma and transgenic H2B-Venus during ES cel
ACS analysis of H2B-VENUS expression during ES differentiation.
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Figure 2 H2B-VENUS+ express smooth muscle cell markers. A–C) Quantitative PCR analysis show the expression of (A) smooth muscle, (B) cardiac and (C) skeletal muscle-related
genes in H2B-VENUS− and H2B-VENUS+ cells sorted from day 6 EBs. cDNA samples obtained from murine E14.5 heart and limb cells and the murine smooth muscle cell line MOVAS were
used as positive controls. Data are mean ± s.e.m. (n = 3). D) Fluorescence image of H2B-VENUS+ cells stained with α-SMA-Cy3 antibody. Scale bar, 50 μm. E) Fluorescent image of cells
of an expanded blast colony stained with α-SMA-FITC antibody. Scale bar, 100 μm. Data represent one of at least 3 independent experiments.
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227Smooth muscle cells largely develop independently of functional hemogenic endotheliumwe differentiated these ES cells for 3 days, sorted FLK1+
cells and replated them in semi-solid blast colony assays.
After 4 days, mature blast colonies were obtained and 96
individual colonies were picked and replated. Upon mor-
phological inspection, all wells were scored positive for the
presence of smooth muscle cells after 12 days. This identity
of the cells was further confirmed by the presence of
nuclear H2B-VENUS fluorescence and cytoplasmic α-SMA
staining (Fig. 2E). Taken together these findings confirm
that smooth muscle cells can be generated from the
hemangioblast.
We next evaluated the generation of smooth muscle cells
during hemangioblast differentiation in the context of
endothelial and hematopoietic development. We therefore
differentiated the α-Sma::H2B-Venus reporter ES cells for
3 days, sorted FLK1+ cells to enrich for BL-CFC and then
plated these cells for 3 days in liquid cultures. Flow
cytometry analysis conducted during these 3 days of differ-
entiation indicated that few H2B-VENUS+ cells were present
by day 1 (Fig. 3A). The percentage of H2B-VENUS+ cells
increased to around 25% by day 3 of blast colony differen-
tiation (Fig. 3A). Interestingly, we found that a large
proportion of H2B-VENUS cells (30 to 50%) also expressed
TIE2, the receptor tyrosine kinase for angiopoietin 1, mostly
associated with endothelial cells (Fig. 3A, top panel).
Nevertheless, these H2B-VENUS+ TIE2+ cells contained lower
α-Sma, Sm22 and Calponin 1 transcript levels than
H2B-VENUS+ negative for TIE2 expression (Fig. 3B). In contrast
to H2B-VENUS+ TIE2+, double positive cells for H2B-VENUS and
tyrosine kinase receptor c-KIT expression were much less
frequent (Fig. 3A, middle panel). c-KIT expression is associat-
ed with blood cell and hemogenic endothelium development
during blast colony development (Lancrin et al., 2009). The
last marker to appear was CD41 (Integrin Itga2b), which
defines hematopoietic commitment both in vivo and in vitro
(Ferkowicz et al., 2003; Mikkola et al., 2003). Only a minute
proportion of H2B-VENUS+ cells stained for CD41 (Fig. 3A,
bottom panel).
We previously showed that blood cells are generated by
hemogenic endothelium cells through a series of distinct
cell populations representing successive stages of commit-
ment. A cell population expressing TIE2 and c-KIT but
negative for the expression of CD41 was shown to contain
the first hemogenic endothelium cells (Lancrin et al.,
2009). Some of these cells then acquire CD41 expression
and correspond to more committed cells that retain
endothelial markers (Sroczynska et al., 2009a). Finally,
complete commitment toward hematopoiesis is observed
through the downregulation of endothelial markers and
acquisition of the pan-hematopoietic marker CD45 expres-
sion. As expected during blast colony development, we
detected the emergence of a population of TIE2+ c-KIT+
cells corresponding to hemogenic endothelium (Fig. 3B).
Interestingly, this cell population was much less frequent
when analysis was performed on H2B-VENUS+ cells than
when performed on the whole cell population (Fig. 3C).
We also observed the emergence of TIE2+ CD41+ cells,
corresponding to more committed hemogenic endothelium
cells that progress to down-regulate TIE2 (Fig. 3D). Again
this cell population was largely under-represented in
H2B-VENUS+ cells. Altogether our results suggest that
while smooth muscle cells can be found within theputative TIE2+ endothelial cell compartment, their pres-
ence in hemogenic endothelium cell populations is much
less evident.Smooth muscle largely develop independently from
functional hemogenic endothelial cells
To directly investigate whether the hemogenic endothelial
cell population contains smooth muscle cells, α-Sma::
H2B-Venus reporter ES cells were differentiated, FLK1+ cells
sorted and replated in liquid cultures. After 2 days the cells
were harvested and stained for hemogenic endothelium
markers. At this stage, most of the cells in culture were
c-KIT− and this c-KIT− cell population included a readily
detectable H2B-VENUS+ fraction (Fig. 4A). In contrast, a much
lower frequency of H2B-VENUS+ cells was detected in the
TIE2+ c-KIT+ CD41− hemogenic endothelium whereas almost
no H2B-VENUS+ cells were observed in the subsequent TIE2+
c-KIT+ CD41+ cell population (Fig. 4A). Only a sub-fraction of
the TIE2+ c-KIT+ CD41− hemogenic endothelium cells corre-
spond to functional hemogenic endothelium able to generate
hematopoietic precursors (Lancrin et al., 2009) suggesting
that rare H2B-VENUS+ cells present within the TIE2+ c-KIT+
CD41− population could correspond to cells different from
functional hemogenic endothelium (able to generate hema-
topoietic precursors). To test this possibility, we separated
the TIE2+ c-KIT+ CD41− cells based on H2B-VENUS expression,
then cultured in hemogenic endothelium medium for 2 days
to allow further maturation and replated in hematopoietic
colony assays. The H2B-VENUS− cell cultures generated blood
cell colonies whereas H2B-VENUS+ population did not produce
any hematopoietic colonies (Fig. 4A). Altogether, these
results demonstrate that the H2B-VENUS+ cells present in
the TIE2+ c-KIT+ CD41− cell population do not represent a
hemogenic endothelium and indicate that functional
hemogenic cells do not express α-Sma.
To further define the relationship between hemogenic
endothelium and smooth muscle, we next asked whether
the hemogenic endothelium could give rise to H2B-VENUS+
smooth muscle cells. For this, we generated α-Sma::
H2B-Venus reporter day 2 blast colony cultures. We first
excluded H2B-VENUS+ cells before sorting the subsequent
TIE2+ c-KIT+ CD41−, TIE2+ c-KIT+ CD41+ and TIE2low c-KIT+
CD41+ cell populations and replated them in hemogenic
endothelium medium (Fig. 4B). At the time of the sort, the
frequency of cells that co-expressed CD45 was extremely
low (Supplemental Fig. 3). The cells were harvested after
two days and analysed for the presence of H2B-VENUS and
CD45, a marker of fully committed blood cells. As shown in
Fig. 4B, all three cell populations generated CD45+ blood
cells. In contrast, the TIE2+ c-KIT+ CD41+ (P2Δ) and TIE2low
c-KIT+ CD41+ (P3Δ) cell populations did not generate
H2B-VENUS+ cells suggesting that these populations do
not have any smooth muscle potential. The TIE2+ c-KIT+
CD41− (P1Δ) produced a very low but not negligible
frequency of H2B-VENUS+ cells. These H2B-VENUS+ cells
are however likely to originate from non hemogenic
endothelium cells still present in this TIE2+ c-KIT+ CD41−
population. Altogether our results indicate that functional
hemogenic cell populations are largely devoid of smooth
muscle potential.
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229Smooth muscle cells largely develop independently of functional hemogenic endotheliumDiscussion
In this study, we investigated the generation of smooth
muscle cells upon in vitro differentiation of ES cells. For
this we engineered a reporter ES cell line in which
expression of the fluorescent protein H2B-VENUS is driven
from α-Sma regulatory sequences. We demonstrated that
the expression of H2B-VENUS is strongly correlated with
α-Sma expression during in vitro differentiation of this
reporter ES cell line. In addition, the enrichment for
expression of a panel of smooth muscle markers indicates
that H2B-VENUS+ cells truthfully represent a smooth muscle
cell lineage. It has been shown that vascular smooth muscle
cells express the long isoform of Smoothelin (Smoothelin-B)
whereas visceral smooth muscle cells express the short
isoform (Smoothelin-A) (Kramer et al., 2001). We detected
in the H2B-VENUS sorted cells mostly transcripts of
Smoothelin-B (Supplemental Fig. 5), suggesting that our
ES differentiation conditions preferentially generate vas-
cular rather than visceral smooth muscle cells. Altogether
these results indicate that H2B-VENUS detection allows
directly quantifying or isolating smooth muscle cells. With
this reporter ES cell line, we also confirmed that clonal
BL-CFCs generate smooth muscle cells. It has been recently
established that BL-CFC generates blood cells through a
hemogenic endothelium intermediate (Lancrin et al.,
2009). To determine if the generation of smooth muscle
cells is associated, or independent, from the emergence of
this hemogenic endothelium, we examined the presence
of H2B-VENUS+ cells in cell subpopulations containing
this precursor. We indeed observed the presence of few
H2B-VENUS+ cells in these hemogenic endothelium popula-
tions. However these cells lacked hematopoietic potential
and therefore did not correspond to functional hemogenic
endothelium, indicating that smooth muscle cells are
largely generated independently form the hemogenic
endothelium.
This early dichotomy between generation of blood and
smooth muscle cells is further supported by previous studies
indicating that while the transcription factor Tal1 (Scl) is
critical for the development of hematopoietic cells (Porcher
et al., 1996; Robb et al., 1996), it strongly antagonises
smooth muscle cell development (Ema et al., 2003; Ema and
Rossant, 2003). Ema et al. showed that increased Tal1
expression in FLK1+ mesodermal cells inhibited smooth
muscle differentiation, whereas loss of Tal1 promoted
smooth muscle formation (Ema et al., 2003). Accordingly
to a dichotomy between generation of blood and smooth
muscle cells, we recently established that Tal1 is critical forFigure 3 Tracking the emergence of smooth muscle cells during
expression of H2B-VENUS in combination with TIE2, c-KIT and CD41 d
α-Sma, Sm22 and Calponin 1 in H2B-VENUS+ TIE2− and H2B-VENUS+ TIE
(n = 3). C) Top panel: FACS analysis of TIE2 and c-KIT expression o
FACS analysis of H2B-VENUS+ gated cells for the expression of TIE2 a
analysis of TIE2 and CD41 expressions on total cells during blast
H2B-VENUS+ cells showing the expression of TIE2 and CD41 during
independent experiments.the generation of hemogenic endothelium and blood but
appears to be dispensable for smooth muscle development
(Lancrin et al., 2010). Altogether these findings are
consistent with an early separation between hemogenic
endothelium and smooth muscle generation during develop-
ment. Whether signalling by smooth muscle contributes to
some extent, as recently suggested, to the generation of blood
cells from hemogenic endothelium is unclear (Clements and
Traver, 2013). The observation that some H2B-VENUS+ cells
generated from FLK1+ mesodermal cells are TIE2+ (Fig. 2)
suggests the possibility of the presence of a bi-potential
vascular progenitor that gives rise to smooth muscle and
endothelial cells. This idea is supported by the fact that
H2B-VENUS+ TIE2+ cells contained smooth muscle-related
transcripts but expressed them at lower levels than
H2B-VENUS+ TIE2−. However, whether the generation of
smooth muscle cells proceeds through a vascular bi-potent
progenitor remains to be proven. Alternatively, TIE2 (but not
other endothelial markers as indicated in Supplemental Fig. 4)
could be expressed in smooth muscle cells independently of
endothelial differentiation potential.
There is a clear clinical interest to use human ES cells or
induced pluripotent stem (iPS) cells to generate endothelial
cells to provide neovascularisation to treat ischemic dis-
eases, that represent one of the major causes of morbidity
and mortality in the world (Chaudhury et al., 2012; Cheung
and Sinha, 2011; Wang et al., 2007). Accumulating evidence
indicate that the addition of vascular smooth muscle to
endothelial cells leads to enhanced engraftment and
vascularization compared with endothelial cells alone
(Foubert et al., 2008; Levenberg et al., 2005; Shepherd et
al., 2009). It is therefore important to develop new, or
improve current, protocols to generate vascular smooth
muscle cells from ES cells (Cheung et al., 2012; Cheung and
Sinha, 2011; Lindskog et al., 2006). Our findings provide new
insights into vascular development from ES cells and indicate
that the α-Sma::H2B-Venus reporter ES cell line is a powerful
new tool to further improve the generation of smooth
muscle cells from ES or iPS cells for vascular grafts.
Supplementary data to this article can be found online at
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